Tirzepatide monograph · Evidence review
Zepbound Cost, Coupons & the Cheapest Ways to Get It (2026)
List price, LillyDirect self-pay vials, the savings card, GoodRx-style coupons and compounded options — an honest, dated breakdown of what Zepbound costs.
Researched & written by Alan Pierce · last updated
Clinical Pharmacology Writer
On this page
Editorial pick
CoreAge Rx
$149/mo flat
Doctor-reviewed tirzepatide with one flat price and built-in human support.
Check availability- vs median
- $109/mo below the $258 median
- Market
- $99–$399/mo across 42 providers
- Brand from
- $349/mo
- Dispensed
- Compounded tirzepatide (503A)
Advertising disclosure · we may earn a commission at no extra cost to you.
Popular alternative
Ageless
Broad compounded storefront pairing $169/month injectable tirzepatide with a rare oral-drop option — plus NAD+, sermorelin, and TRT under one roof.
$169/mo injectable
Check Ageless availabilityZepbound (tirzepatide) is one of the most effective obesity medications ever brought to market — and one of the most expensive to pay for out of pocket. If your insurance covers it, your cost can be small. If it doesn't, the gap between the headline "list price" and what people actually pay is enormous, and it changes depending on which route you take. This guide lays out every legitimate path to a lower price, with real, dated numbers, and is honest about where the cheap-looking options carry trade-offs.
Two ground rules first. Zepbound is prescription-only — its FDA label authorizes it for chronic weight management in adults with obesity, or overweight with a weight-related condition, alongside diet and exercise1. No coupon, vial program, or compounding pharmacy changes that; you need a clinician and a prescription. And this is a cost guide, not financial or medical advice — prices move, insurance rules differ by plan, and the right choice is the one you make with a prescriber and your own coverage in front of you.
The list price: roughly $1,000+ a month
The "list price" (also called WAC, the wholesale acquisition cost) is the manufacturer's sticker price before any insurance or discount. For Zepbound's single-dose pens it sits around $1,086 for a one-month (4-pen) supply2. Almost nobody who is paying attention actually pays this — it's the number coupons and self-pay programs are designed to beat — but it matters because it's the figure your insurance's cost-sharing is calculated against, and the anchor a pharmacy will quote you if you walk in with no coverage and no discount card.
LillyDirect self-pay vials: the cheapest cash route
The biggest single lever for uninsured or under-covered patients is LillyDirect, Lilly's own direct-to-consumer pharmacy, which sells Zepbound as single-dose vials (you draw the dose into a syringe yourself) at a steep discount to the pen list price — a format choice we break down in detail in Zepbound vials vs pens: the self-pay price difference. As of the price reduction effective February 23, 2026, the Zepbound Self Pay Journey Program prices are3:
- 2.5 mg vial — about $299/month (the starting dose)
- 5 mg vial — about $399/month
- 7.5 mg, 10 mg, 12.5 mg and 15 mg vials — about $449/month
A "month" here means a 28-day supply of four single-dose vials. There are caveats worth knowing: the $449 price on the higher doses is tied to refilling within 45 days of your previous shipment — let the refill lapse and the 12.5 mg and 15 mg vials revert to higher prices (around $849 and $1,049)3. The vial format is also less convenient than the auto-injector pen: you draw up the dose yourself, so you have to be comfortable with a syringe (our guide to how to inject Zepbound and how many units 2.5 mg of tirzepatide is walk through the mechanics). When LillyDirect first launched self-pay vials in mid-2025 the starting dose was $349; the early-2026 cut to $299 is the current floor4.
The Zepbound Savings Card: best if you have commercial insurance
Lilly's manufacturer savings card is the other major discount, but its value depends entirely on your insurance status5:
- If you have commercial insurance that covers Zepbound: you may pay as little as $25 for a 1-, 2-, or 3-month fill, with savings capped (up to $1,300 per calendar year).
- If you have commercial insurance that does NOT cover Zepbound: the card brings the single-dose pen down to $499/month (up to 13 fills a year). If you can use the KwikPen instead, that route runs at the self-pay ladder — $299/$399/$449 by dose — with a lower annual fill cap, so it is worth asking which form your prescription is written for.
The single most important restriction: the savings card excludes anyone enrolled in a government program — Medicare, Medicaid, the VA, TRICARE and similar are not eligible5. That exclusion is the reason so many Medicare-age patients end up on the self-pay vial route instead. (We cover the coverage maze — Aetna, BCBS, Medicare and prior authorization — in our companion guide on whether insurance covers Zepbound, and the Medicare-specific rules in does Medicare cover tirzepatide?.)
GoodRx-style coupons: useful, but rarely the cheapest here
If you want this sorted by what you personally qualify for rather than route by route, see which Zepbound discount you're eligible for. Discount-card services like GoodRx, SingleCare and similar negotiate cash prices at retail pharmacies, and they're genuinely worth checking — for many drugs they beat everything else. For Zepbound specifically, the coupon price at a retail pharmacy usually lands close to or above the LillyDirect self-pay vial price, because Lilly has priced its own direct channel aggressively to compete. Treat a pharmacy-coupon quote as a number to compare against the $299–$449 vial pricing, not assume it will win. Coupon prices also swing pharmacy to pharmacy and week to week, so a quote is a snapshot, not a guarantee. Importantly, you generally cannot stack a manufacturer savings card and a third-party discount coupon on the same fill — you pick the one that's cheaper.
Compounded tirzepatide: cheaper, but a different — and now restricted — product
During the 2022–2024 tirzepatide shortage, compounding pharmacies were permitted to make copies of tirzepatide, and they advertised prices well below brand Zepbound. That window has effectively closed. The FDA declared the tirzepatide shortage resolved on October 2, 2024, and the enforcement-discretion period that had allowed routine compounding ended — for state-licensed (503A) pharmacies around February 18, 2025, and for outsourcing (503B) facilities around March 19, 20256. The FDA has further proposed excluding tirzepatide from the 503B bulk-substances list6; we walk through the full regulatory timeline and what counts as legal in is compounded tirzepatide still legal in 2026?.
What this means honestly: large-scale compounding of tirzepatide "because of the shortage" is no longer a sanctioned path. Some sellers still market compounded versions, sometimes as salt forms (e.g., tirzepatide acetate) or via narrow personalization exceptions, but these are not FDA-approved products, are not the molecule studied in the trials below, and have been the subject of FDA warning letters and safety concerns about purity, dosing and sourcing. If you see compounded tirzepatide priced far under the LillyDirect vials, treat the savings as a red flag, not a deal, and ask exactly what is being dispensed and under what authority. The branded, self-pay vial route is the cheaper legitimate option for most people. If you are weighing a compounded program anyway, at least do it with the whole field in front of you: we sort every tirzepatide program by the price it publishes, cheapest first, and print the conditions attached to each headline rate. Those conditions are usually where the discount actually lives: Bodybuilding Health+, for instance, only reaches its lowest advertised monthly figure on a twelve-month prepaid bundle, which is a very different commitment from a month-to-month price of the same size.
What actually drives your cost
Boiling it down, four things move your monthly bill:
- Insurance coverage. A plan that covers Zepbound for obesity (not all do — many cover it only for type 2 diabetes or sleep apnea, or not at all) plus the savings card is by far the cheapest scenario.
- Pen vs. vial. The auto-injector pen is convenient and carries the high list price; the LillyDirect self-pay vial is cheaper but you self-draw the dose.
- Government insurance. Medicare/Medicaid enrollment locks you out of the savings card, pushing you toward self-pay vials.
- Your dose. Self-pay vial pricing tiers by strength (2.5 mg cheapest, 7.5 mg+ flat at the top tier), and refill timing affects the higher doses. Our tirzepatide dosage chart and look at the most effective Zepbound dose explain why most people don't stay on the cheapest starting dose for long.
§ Table 1 — Zepbound Pricing Routes (Effective Feb 23, 2026)
| Route | Best for | Approx. monthly cost | Key restrictions |
|---|---|---|---|
| Commercial insurance + savings card | Covered commercial plan members | As low as $25/month | Up to $1,300/yr savings cap; excludes Medicare/Medicaid/VA |
| Savings card — no Zepbound coverage | Commercial insurance, drug not covered | $499/month (single-dose pen) | ≤13 fills/year; KwikPen instead runs $299–$449; excludes government programs |
| LillyDirect self-pay vials — 2.5 mg | Uninsured / government insurance | ~$299/month | Self-draw syringe; 45-day refill rule (higher doses) |
| LillyDirect self-pay vials — 5 mg | Uninsured / government insurance | ~$399/month | Same 45-day refill rule |
| LillyDirect self-pay vials — 7.5–15 mg | Uninsured / government insurance | ~$449/month | Lapses beyond 45 days revert to $849–$1,049 |
| GoodRx / pharmacy coupon | All — check vs vial price | Varies (often near vial price) | Cannot stack with manufacturer savings card |
| Pen list price (no discount) | Reference only | ~$1,086/month | Almost never the actual paid price |
To put your own numbers in — format, dose tier, insurance route and any membership fee — try our Zepbound cost calculator for a quick monthly and annual out-of-pocket estimate (verify the result on LillyDirect).
Is it worth the cost? What the evidence says
Cost only means something next to results, and Zepbound's results are the reason it commands its price. In SURMOUNT-1, the pivotal 72-week obesity trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5 mg, 10 mg and 15 mg doses, versus about 3% on placebo7. Head-to-head against semaglutide (Wegovy) in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14% over 72 weeks8. That efficacy is real and trial-grade; it's also why no discount makes the drug cheap, just less expensive. The honest framing: Zepbound is a long-term medication — weight tends to return after stopping — so the cost is best understood as an ongoing one, not a one-time purchase. Whether that ongoing price is justified by the results is exactly the trade-off we weigh in is Zepbound worth it?. Our tirzepatide evidence guide lays out the full efficacy and safety picture, and our look at stopping tirzepatide covers the regain question that makes ongoing cost so relevant.
The cheapest path, in order
For most people without Zepbound-specific insurance coverage, the priority order in 2026 looks like this: (1) check whether your commercial plan covers it and use the $25 savings card if so; (2) if you have commercial insurance but no Zepbound coverage, the savings card gets the single-dose pen to $499 (or the KwikPen to $299–$449); (3) if you're uninsured or on a government plan, LillyDirect self-pay vials at $299–$449 are the cheapest legitimate route; (4) price-check a GoodRx-style coupon against those vial numbers; and (5) treat deeply discounted compounded tirzepatide with skepticism given the post-shortage restrictions. Whatever route you choose, you still need a prescriber — and to compare vetted telehealth and pharmacy options (and avoid paying for a compounded copy when you wanted brand Zepbound), see our best place to get Zepbound online roundup, our provider-by-provider Ro tirzepatide review, and our guide to the best tirzepatide providers. If you would rather read the raw numbers than a ranking, our tirzepatide price index lists every tracked program's monthly price with the dose tier and the brand-versus-compounded form attached to it, and publishes the same table as CSV and JSON.
Frequently asked questions
What is the cheapest way to get Zepbound without insurance?
For most uninsured patients, LillyDirect self-pay single-dose vials are the cheapest legitimate route — about $299/month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for 7.5 mg and higher (28-day supply, prices effective Feb 23, 2026). You draw the dose yourself with a syringe rather than using a pen. Always price-check a GoodRx-style coupon against those numbers.
How much does Zepbound cost with the savings card?
If you have commercial insurance that covers Zepbound, the manufacturer savings card can bring your cost as low as $25 for a 1-, 2-, or 3-month fill (up to a $1,300/year cap). If you have commercial insurance that doesn't cover it, the card brings the single-dose pen to $499/month (up to 13 fills a year); the KwikPen form instead runs at the self-pay ladder of $299–$449 by dose. The card excludes anyone on Medicare, Medicaid, the VA or TRICARE.
Is compounded tirzepatide still available and is it cheaper?
Large-scale compounding of tirzepatide ended after the FDA declared the shortage resolved (Oct 2, 2024); enforcement discretion ended around Feb–Mar 2025. Some sellers still market compounded versions, but they are not FDA-approved, are not the molecule studied in the trials, and have drawn FDA warnings. The branded LillyDirect self-pay vials are the cheaper legitimate option for most people.
Why is Zepbound so expensive?
Its list price is roughly $1,086 a month for the pens. The price reflects trial-grade efficacy — about 15–21% average weight loss over 72 weeks in SURMOUNT-1 — and the reality that it's a long-term medication, since weight tends to return after stopping. Discounts reduce the cost but don't make it cheap.
References(8)
- Eli Lilly and Company (manufacturer label) (2024). Zepbound (tirzepatide) injection — FDA prescribing information (Indications and Usage; prescription-only Rx status). DailyMed (NIH/NLM), FDA label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Eli Lilly and Company (2026). Zepbound Cost Information — list price and self-pay / savings overview. Lilly (pricinginfo.lilly.com). https://pricinginfo.lilly.com/zepbound
- Eli Lilly and Company (Investor Relations) (2026). Lilly lowers the price of Zepbound (tirzepatide) single-dose vials (effective Feb 23, 2026: 2.5 mg $299, 5 mg $399, all other doses $449; 28-day/4-vial supply; 45-day refill condition). Lilly Investor News Release. https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials
- PharmExec (Pharmaceutical Executive) (2025). Lilly Launches Full Zepbound Dose Access for Obesity Through LillyDirect Self-Pay Program (June 16, 2025 launch; original $349 starting-dose pricing). Pharmaceutical Executive. https://www.pharmexec.com/view/lilly-launches-full-zepbound-dose-access-obesity-lillydirect-self-pay-program
- Eli Lilly and Company (2026). Savings Options — Zepbound (tirzepatide): savings-card terms ($25 covered; $499 not covered, single-dose pen; $1,300/yr cap; government beneficiaries excluded). Lilly (zepbound.lilly.com/savings). https://zepbound.lilly.com/savings
- U.S. Food and Drug Administration (2025). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved Oct 2, 2024; 503A discretion ended ~Feb 18, 2025; 503B ~Mar 19, 2025). FDA Drug Alerts and Statements. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Related monograph sections
View allMochi Health Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)
An honest 2026 review of Mochi Health's tirzepatide — cost, the compounded-vs-brand question, how the telehealth model works, and the catches.
ReadRo Tirzepatide Review: Cost, How It Works & Honest Verdict (2026)
An honest 2026 review of Ro's tirzepatide (Zepbound) program — how much it costs, how the telehealth model works, brand vs compounded, and the catches.
ReadHenry Meds Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)
An honest 2026 review of Henry Meds' tirzepatide — cost, the compounded-vs-brand question, how the flat-fee telehealth model works, and the catches.
ReadCoreAge Rx Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)
An honest 2026 review of CoreAge Rx tirzepatide — the flat $149/month price, 503A compounding, included nurse and dietitian support, and the catches.
ReadAgeless Tirzepatide Review: Cost, Oral Drops & Honest Verdict (2026)
An honest 2026 review of Try Ageless tirzepatide — $169/month injectable, a rare oral-drops option, the compounded caveat, and the transparency gaps.
ReadFound Tirzepatide Review: Cost, Brand vs Compounded & Honest Verdict (2026)
An honest 2026 review of Found's tirzepatide — its broad formulary with real brand Zepbound/Mounjaro plus compounded, the layered pricing, and the catches.
Read